Register

For access to our Knowledge Centre and Newsletters please register with us.

Alternatively, If you already have an account, please login.

You are in:
About Us >
Meet the Team >
Team Member

Team Member

Director - Professor Adrian Towse

Adrian has 20 years’ experience in the economics of the health and pharmaceutical industries. He joined the OHE in 1993. He is a Visiting Professor at the University of York and a visiting Senior Researcher at the Department of Public Health and Primary Care at the University of Oxford. He served for ten years as Non-executive Director of the Oxford Radcliffe Hospitals NHS Trust, one of the UK’s largest hospitals. He also chairs the Health Economics Action Group which comprises the heads of global health outcomes of the major companies. His current research interests include the use of "risk-sharing" arrangements between health care payers and pharmaceutical companies; the economics of pharmacogenetics for health care payers and the pharmaceutical industry; economic issues around access to, and R&D for the development of, treatments for less developed country diseases; the economics of medical negligence; and measuring productivity in health care

Adrian Towse has an MA (Hons) in Politics, Philosophy and Economics, Keble College, Oxford, an MPhil in Management Studies, from Nuffield College, Oxford and the Oxford Centre for Management Studies, and is a Member of the Chartered Institute of Management Accountants

Selected Journal Articles & Working Papers

Papers in progress

Towse 2010. Value Based Pricing, R&D and Patient Access Schemes. Will the UK get it right or wrong? British Journal of Clinical Pharmacology. In print

Towse and Danzon "The Regulation Of The Pharmaceutical Industry" forthcoming in the Oxford Handbook on Regulation, OUP 2010

Garau, Shah, Mason, Wang, Towse, Drummond. Using QALYs in cancer: a review of the methodological limitations. Submitted to Value in Health.

Towse and Dawson "Health care productivity change: Cost reducing or quality enhancing? Health Economics Study Group paper.

Towse "Demonstrating cost-effectiveness. Can we use risk-sharing rather than one-off decisions at launch?" Health Economics Study Group paper.

2010

Towse A and Garrison LP. "Can’t Get No Satisfaction? Will Pay for Performance Help? Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products". Pharmacoeconomics. 2010; 28(2): 93-102.

2009

Towse A. Should NICE’s threshold range for cost per QALY be raised? Yes. BMJ.2009: 338:b181.

2007

Garrison LP, Towse A, and Bresnahan B. Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis. Health Affairs 26, no. 3 (2007): 684–695; 10.1377/hlthaff.26.3.684

Mason A, Towse A (eds) 2007. The ideas and influence of Alan Williams. Be reasonable - do it my way!. New York: Radcliffe Publishing, Oxford.

2006

Drummond M, Mason A, Towse A. The desirability and feasibility of economic studies post-launch. European Journal of Health Economics. March 2006 1(7):5-6.

Mason A, Drummond M, Towse A. Economic post-launch studies: matching the desirable with the feasible. London: Office of Health Economics; 2006 September.

Towse and Buxton. Notes on a Conference in Honour of Bernie O’Brien. Three Challenges to Achieving Better Analysis for Better Decisions: Generalisabilty, Complexity and Thresholds. Office of Health Economics, London, 2006.

2005

Barbieri, Drummond, Willke, Chancellor, Jolain, Towse, "Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability" Value in Health Volume 8, No 1, 2005.

Cooke, Mason, Drummond, Towse, Medication Management in English National Health Service" American Journal Health-System Pharmacy,2005:62 .

Dawson D, Drummond M, Towse . A. European integration and the economics of health care. In: Smith P, Ginnelly L, Sculpher M, editors. Health policy and economics: opportunities and challenges: 2005.Maidenhead: Open University Press;. pp. 248-271.

Mason, Drummond, Hunter, Towse, Cooke, "Prescribing Incentive Schemes" Applied Health Economics for Health Policy 2005: 4 (2): 111-117

Towse. "Commentary on Basic research funds to discover important new drugs: who contributes how much?" Chapter 3 of Monitoring Financial Flows for Health Research: Behind the Global Numbers. Global Forum for Health Research. Helping Correct the 90:10 Gap, Geneva.

Towse and Kettler, 2005. "Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies". Bulletin of the World Health Organization, 83 (3).

Towse and Kettler, 2005 "A Review of IP and Non-IP Incentives for R&D for Diseases of Poverty. What Type of Innovation is Required and How Can We Incentivise the Private Sector to Deliver It?" Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH), World Health Organization, Geneva, 2005.

2004

Fenn, Gray, Rickman, Towse, 2004 "Making amends for negligence" BMJ, 328: 417 - 418.

Danzon and Towse, "Theory and Implementation of Differential Pricing for Pharmaceuticals in International Public Goods and Transfer of Technology under a Globalised Intellectual Property Regime" edited by Keith E. Maskus and Jerome H. Reichman, eds. 2004 Cambridge Press.

Geneva: The Initiative on Public-PrivatePartnerships for Health, Global Forum for Health Research.

Mason, Drummond, Towse, Cooke, 2004 "Influencing prescribing in English primary care: the views of primary care organisations" Journal of Health Services Research & Policy, Vol 9 No3

Ossa and Towse, 2004 "Genetic Screening, Health Care and the Insurance Industry: Should Genetic Information be made available to Insurers? European Journal of Health Economics

Towse, Mestre-Ferrandiz, Renowden, "Estimates of the medium-term financial resource needs for development of pharmaceuticals to combat ‘neglected diseases’" Annex 9A in "Combating Diseases Associated with Poverty - Financing Strategies for Product Development and the Potential Role of Public-Private Partnerships" IPPH, Global Forum for Health Research, Nov 2004

Towse, Mills, Tangcharoensathien 2004 "Learning from Thailand's health reforms" BMJ, 328: 103 - 105.

2003

Danzon and Towse "Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents" Journal of Health Care Financing and Economics Volume 3, Issue 3, Sep 2003 Pages: 183-205

Garrison and Towse, "The Drug Budget Silo Mentality in Europe: An Overview" Value in Health, Volume 6, Issue s1, Page S1-S9, Jul 2003

Towse, "The Efficient Use of Pharmaceuticals: Does Europe Have Any Lessons for a Medicare Drug Benefit? Health Affairs 2003 Vol 22 No 3.

A. Towse and D. Jamison (2003) "The R&D process for new drugs and vaccines: The case of neglected diseases,"Draft paper for the World Bank Technical Consultative Group on Health and Pharmaceuticals.

Towse, Fenn, Gray, Rickman, Salinas, "Reducing Harm to Patients in the National Health Service. 2003. Will the Government’s Compensation Proposals Help? Office of Health Economics

2002

Danzon and Towse, "The Economics of Gene Therapy and of Pharmacogenetics" Value in Health Vol5 No1 2002 :5-13

Devlin and Towse, "What research is required?" In Towse, Pritchard and Devlin (eds). Cost-effectiveness Thresholds. Economic and Ethical Issues. Kings Fund and Office of Health Economics., 2002

Kettler and Towse, "Public Private Partnerships. A Report for the WHO Macroeconomic Commission on Health". Published as "Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty" by the Office of Health Economics 2002.

Mason, Towse, Drummond, Cooke, "Influencing Prescribing in a Primary Care Led NHS". Office of Health Economics, 2002.

Towse, Pritchard and Devlin (eds.) Cost-effectiveness Thresholds. Economic and Ethical Issues. Kings Fund and Office of Health Economics., 2002

Towse and Pritchard, "Does NICE have a threshold? An external view". In Towse, Pritchard and Devlin (eds.) Cost-effectiveness Thresholds. Economic and Ethical Issues. Kings Fund and Office of Health Economics., 2002

Towse and Pritchard, "National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working?" Pharmacoeconomics 2002:20 Suppl. 3:95-105

2000

Danzon and Towse 2000. The Genomic Revolution: Is the Real Risk Under-investment Rather than Bankrupt Health Care Systems?" J. Health Services Research and Policy, 5(4),

Sussex and Towse, "Getting EU expenditure up to the EU mean. What does that mean?" BMJ, March 2000 Vol 320 No 7235: 640-642

1999

Mason, Towse, Drummond, "Disease Management, the NHS and the Pharmaceutical Industry." Office of Health Economics, 1999.

Mason, Drummond and Towse, "Is disease management relevant in Europe: some evidence from the United Kingdom". Health Policy 1999 vol 48 69:77

Mason, Drummond and Towse, "Joint disease management ventures in the UK", Journal of Integrated Care, 1999: 71-78

Pritchard and Towse, "Methodologies used to evaluate and measure the economic outcomes of drug treatments", in Salek (editor) Pharmacoeconomics and Outcome Assessment, A Global Issue, 1999: 33-52

Towse and Danzon, "Medical Negligence and the NHS: An Economic Analysis", Health Economics 8, 1999: 93-101

Towse and Leighton, "The changing nature of NCE pricing of second and subsequent entrants." In Sussex and Marchant (eds) Risk and Return in the Pharmaceutical Industry. Office of Health Economics, 1999.

1998

Towse, "The Pros and Cons of a Single 'Euro-Price' for Drugs", PharmacoEconomics, 13 (3): 271-6, 1998

Towse & Drummond (ed) From Efficacy to Cost-Effectiveness [OHE Briefing No.37]May 1998

1997

Cave and Towse, "Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry", OHE, 1997.

A Towse (ed) Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK Learn from Australia and Canada? OHE. May 1997

Towse "The Development and Use of the UK Government: ABPI Guidance" in Towse, edited "Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?", OHE, 1997.

Towse and Drummond (editors) "The Pros and Cons of Modelling in Economic Evaluation", OHE, 1997.

1995

Hale and Towse "Value of the Pharmaceutical Industry to the Economy", OHE, 1995.

Towse (editor) "Industrial Policy and the Pharmaceutical Industry", OHE, 1995.

Towse "An overview of the NERA proposals for health care reform" in Towse (editor) "Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS", OHE, 1995.

1994

Towse & Teeling Smith, "The economics of healthcare" in Griffin, O’Grady, Wells, edited "Textbook of Pharmaceutical medicine 2nd edition, 1994.

1993

Towse A, D'Arcy, P F Y, Harron. D W G. Not What the Doctor Ordered - the Threat of Medicines Substitution. OHE,1993.